FRAMINGHAM, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical ...
FRAMINGHAM, Mass., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Arch Therapeutics kicked off a trial of its AC5 Surgical ...
FRAMINGHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical ...
AC5® Advanced Wound System to be Featured in the Hands-On Skills Lab for Clinicians and a Clinical Case Poster Demonstrating Utility in Treatment of Venous Leg Ulcers FRAMINGHAM, Mass., Nov. 02, 2023 ...
SAWC Fall provides a venue to educate clinicians about AC5 Advanced Wound System, present case studies, and continue strategic meetings with wound care companies. FRAMINGHAM, Mass., Oct. 01, 2024 ...
FRAMINGHAM, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“ Arch ” or the“ Company ”), a marketer and developer of novel self-assembling wound care and biosurgical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results